Core Insights - King Faisal Specialist Hospital and Research Centre (KFSHRC) will participate in the C3 Davos of Healthcare™ summit in Japan on September 24, 2025, focusing on international collaboration in healthcare [1][2] - KFSHRC's CEO, Dr. Majid Alfayyadh, will deliver a keynote speech on the vision for integrated healthcare and investment in modern medical infrastructure in Saudi Arabia [1] - KFSHRC has been recognized as the top academic medical center in the Middle East and Africa and ranked 20th globally according to the 2024 Brand Finance rankings [3] Group 1 - The summit theme is "Trilateral Cooperation: Bridging Borders in Healthcare," aimed at fostering international dialogue and collaboration among global leaders, policymakers, investors, and innovators [1] - Dr. Alfayyadh will discuss Saudi Arabia's strategy for building a patient-centered healthcare ecosystem, emphasizing digital health, hospital expansion, and medical education initiatives [1][2] - The participation of KFSHRC signifies a new chapter in its global engagement, aligning with its mission to promote medical excellence and elevate Saudi Arabia's healthcare sector to a world-leading level [2] Group 2 - KFSHRC's thought leaders will engage in strategic discussions on healthcare transformation, including opportunities for collaboration in biotechnology, robotics, and elderly care [2] - The Assistant CEO, Dr. Osama AlSwailem, will focus on integrating healthcare data and genomics into AI models for rare disease identification, highlighting advancements in data science and precision medicine [2] - KFSHRC's participation in the summit aims to strengthen global alliances dedicated to accelerating innovation and improving health outcomes across borders [2]

Group 1 - Fresenius Medical Care has invested EUR 312 million and successfully closed a share purchase agreement with all non-physician investors in Interwell Health (IWH) [1] - This investment accelerates the timeline originally set during the merger of Cricket Health, IWH, and Fresenius Health Partners, which was completed in August 2022 [1] - Tommy P. O'Connor has been appointed as CEO of Interwell Health and Operating Segment leader of Value-Based Care to enhance the benefits of vertical integration and accelerate value creation in line with the FME Reignite strategy [1]

As filed with the Securities and Exchange Commission on September 17, 2025 Registration No. 333-286850 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Safe & Green Holdings Corp. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 5030 95-4463937 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identifi ...

Group 1 - Solventum (SOLV) is one of 974 companies in the Medical group, which is currently ranked 7 within the Zacks Sector Rank [2] - Solventum has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook with a 6.1% increase in the consensus estimate for full-year earnings over the past quarter [3] - Year-to-date, Solventum has gained approximately 10.8%, outperforming the Medical sector, which has returned an average of -2.7% [4] Group 2 - Solventum is part of the Medical Services industry, which consists of 58 companies and is currently ranked 99 in the Zacks Industry Rank, with a year-to-date loss of about 2.6% [5] - ANIXA BIOSCIENCES INC (ANIX) is another Medical stock that has outperformed the sector with a return of 51.7% year-to-date and has a Zacks Rank of 2 (Buy) [4][5] - The Medical - Biomedical and Genetics industry, to which ANIX belongs, has a total of 485 stocks and is currently ranked 105, with a year-to-date increase of 2.8% [6]

Group 1: Stock Performance - CVS Health's stock decreased by 1.98% to $73.50, underperforming the S&P 500 which gained 0.47% [1] - Over the past month, CVS Health's shares increased by 9.3%, outperforming the Medical sector's gain of 5.49% and the S&P 500's gain of 2.32% [1] Group 2: Earnings Projections - CVS Health is expected to report earnings of $1.36 per share, reflecting a year-over-year growth of 24.77% [2] - Revenue is projected at $97.96 billion, an increase of 2.65% from the same quarter last year [2] Group 3: Fiscal Year Estimates - For the fiscal year, earnings are estimated at $6.34 per share, indicating a growth of 16.97% [3] - Revenue for the fiscal year is projected to be $391.11 billion, representing a 4.91% increase from the previous year [3] Group 4: Analyst Estimates and Confidence - Recent adjustments to analyst estimates for CVS Health indicate changing near-term business trends, with positive revisions suggesting confidence in performance [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks CVS Health at 3 (Hold) [6] Group 5: Valuation Metrics - CVS Health has a Forward P/E ratio of 11.82, which is lower than the industry's Forward P/E of 16.7, indicating a valuation discount [7] - The PEG ratio for CVS Health is 0.83, compared to the Medical Services industry's average PEG ratio of 1.5 [7] Group 6: Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 148, placing it in the bottom 41% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Performance - Teladoc's stock closed at $7.49, down 3.97%, underperforming the S&P 500's daily gain of 0.3% [1] - Over the past month, Teladoc shares appreciated by 13.54%, outperforming the Medical sector's gain of 7.07% and the S&P 500's gain of 2.09% [1] Earnings Projections - The upcoming earnings release projects an earnings per share (EPS) of -$0.24, a 26.32% decrease from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is $625.56 million, down 2.33% from the year-ago period [2] Full Year Estimates - For the full year, the Zacks Consensus Estimates project an EPS of -$1.17 and revenue of $2.52 billion, reflecting changes of +80.07% and -1.82% respectively from the preceding year [3] - Recent changes to analyst estimates indicate a shifting business landscape, with positive revisions suggesting optimism about the business outlook [3] Zacks Rank and Industry Position - The Zacks Rank system, which assesses estimate changes, currently ranks Teladoc as 3 (Hold) [5] - The Medical Services industry, part of the Medical sector, holds a Zacks Industry Rank of 146, placing it in the bottom 41% of over 250 industries [6]

Albion Enterprise VCT PLC Interim Management Statement LEI Code: 213800OVSRDHRJBMO720 Introduction I present Albion Enterprise VCT PLC (the “Company”)’s interim management statement for the period from 1 April 2025 to 30 June 2025. Performance and dividends The Company's unaudited net asset value (“NAV”) on 30 June 2025 was £277.3 million or 115.72 pence per share (excluding treasury shares), a decrease of 0.50 pence per share (0.4%) since 31 March 2025. After accounting for the first dividend for the year ...

Group 1: Company Performance - CVS Health shares have increased by 17.1% over the past month, reaching a 52-week high of $73.23, and have gained 63% since the start of the year, outperforming the Zacks Medical sector and the Zacks Medical Services industry, which saw gains of -2.3% and 0.7% respectively [1] - The company has a strong record of positive earnings surprises, having beaten earnings consensus estimates in the last four quarters, with the latest EPS reported at $1.81 against a consensus estimate of $1.47, and revenue exceeding estimates by 5.54% [2] Group 2: Earnings Projections - For the current fiscal year, CVS Health is expected to report earnings of $6.32 per share on revenues of $390.17 million, reflecting a 16.61% increase in EPS and a 4.66% increase in revenues [3] - For the next fiscal year, earnings are projected to be $7.14 per share on revenues of $408.98 million, indicating a year-over-year change of 12.94% in EPS and 4.82% in revenues [3] Group 3: Valuation Metrics - CVS Health has a Value Score of A, with Growth and Momentum Scores of C and F respectively, resulting in a VGM Score of B, indicating it is a suitable choice for value investors [6][8] - The stock trades at 11.6X current fiscal year EPS estimates, below the peer industry average of 17.7X, and at 8.1X trailing cash flow compared to the peer group's average of 10.5X, with a PEG ratio of 0.81 [7] Group 4: Zacks Rank - CVS Health holds a Zacks Rank of 2 (Buy), supported by a solid earnings estimate revision trend, making it a favorable option for investors seeking stocks with strong potential [8] Group 5: Industry Comparison - CVS Health remains a strong choice within the Medical Services industry, which ranks in the bottom 64% of all industries, but still shows promising tailwinds alongside peers like Progyny, Inc. [9][11]

Financial Performance - The Group achieved a consolidated pro-forma turnover of RON 1.57 billion in H1 2025, a 20.3% increase compared to H1 2024 [19] - Pro-forma EBITDA increased by 21.2% to RON 234.2 million, with a margin of 16.1% [34] - IFRS Revenues recorded a solid 20% increase, with 16.2% driven by organic growth [50] - Net cash from operating activities declined by 41% compared to the same period last year [60] Acquisitions and Investments - The Group finalized the acquisition of Routine Med Group in Tulcea in February [21] - A majority stake in All Clinic in the Republic of Moldova was acquired in March [21] - The acquisition of Medstar Clinic Group in Cluj-Napoca was announced in June, with 2024 revenues of approximately RON 32 million [22] - The company launched the first AI assistant integrated into its mobile app [25] - The company enhanced its diagnostic infrastructure with the 2nd automated laboratory line in the Group, with an investment of over EUR 2 million [26] - The company acquired the Illumina sequencing technology with an initial investment of EUR 3 million [27] Operational KPIs - Hospitals revenue increased by 37.8% to RON 437.787 million [50] - Clinics revenue increased by 20.3% to RON 586.623 million [50] - Laboratories revenue increased by 18.4% to RON 172.790 million [50]

Core Insights - The article compares two Medical Services stocks, Cencora (COR) and Medpace (MEDP), to determine which is more attractive for value investors [1] Valuation Metrics - Both COR and MEDP currently have a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions for both companies [3] - COR has a forward P/E ratio of 18.30, while MEDP has a forward P/E of 33.85 [5] - COR's PEG ratio is 1.38, compared to MEDP's PEG ratio of 2.98, suggesting COR is expected to grow earnings at a more favorable rate [5] - COR has a P/B ratio of 25.49, while MEDP's P/B ratio is significantly higher at 77.18 [6] - Based on these valuation metrics, COR holds a Value grade of A, whereas MEDP has a Value grade of D, indicating that COR is currently the superior value option [6]